



Solid Tumor Oncology

Anatomic Pathology

Morphology

Surgical Pathology Consultation [SPC]
Surgical Pathology Professional [SPP]

Immunohistochemistry & Special Stains

Refer to A-Z listing for IHC Markers

Molecular Oncology

Next Generation Sequencing (NGS)

BRAF Mutation Analysis [M BRAF]
Colorectal Cancer NGS [M COLON NGS]
BRAF, KRAS, NRAS
EGFR Mutation Analysis [M EGFR]
GIST NGS - KIT, PDGFRA, BRAF [M ST NGS GIST]
IDH1/IDH2 Mutation Analysis [M IDH1/2]
KRAS Mutation Analysis [M KRAS]
Lung Cancer NGS [M LUNG NGS]
BRAF, EGFR, KRAS, NRAS
Melanoma Cancer NGS [M MELAN NGS]
BRAF, KIT, NRAS

Fluorescence in situ Hybridization (FISH)

ALK 2p23 rearrangement [FP ALK]
BCL6 3q27 rearrangement [FP BCL6]
Burkitt / "Double Hit" Large B-cell Lymphoma Panel
[FP BURKITT] C-MYC, BCL2, BCL6
C-MYC 8q24 rearrangement [FP CMYC]
EGFR amplification 7p11.2 [FP EGFR*]
HER2/neu Breast Cancer [FP HER2]
HER2/neu Gastric Cancer [FP HER2 GA]
IGH 14q32 rearrangement [FP IGH*]
IGH/BCL1 (CCND1) t(11;14) [FP BCL1]
IGH/BCL2 t(14;18) [FP BCL2]
IGH/MALT1 t(14;18) [FP IGH MALT]
IGH/MYC t(8;14) [FP IGH MYC*]
MALT1 18q21 rearrangement [FP MALT]
Oligodendroglioma, 1p-;19q- [FP GLI*]
ROS1 6q22.1 rearrangement [FP ROS1]

Hematology Oncology

Anatomic Pathology

Morphology

Bone Marrow Pathology Evaluation [BMPE]
Surgical Pathology Consultation [SPC]
Surgical Pathology Professional [SPP]

Immunohistochemistry & Special Stains

Refer to A-Z listing for IHC Markers

Cytogenetics

Chromosome Analysis Bone Marrow [CYTO BM]
Chromosome Analysis Lymphoma (Lymph Node) [CYTO LN]
Chromosome Analysis Leukemic Peripheral Blood [CYTO LPB]

Flow Cytometry

Flow Cytometry Leukemia / Myeloma / Lymphoma [FLOW]
Flow Cytometry Technical Only [FLOW TC]
Flow Cytometry and Morphology [FLOW M]
Bronchoalveolar Lavage [FLOW BAL]
CD3, CD4, CD8, CD16, CD45, CD4:CD8 ratio
Leukocyte Adhesion Deficiency -CD11a, CD11b, CD11c, CD18
[FLOW LAD*]
Paroxymal Nocturnal Hemoglobinuria - High Sensitivity
FLAER, CD14, CD24, CD59 [FLOW PNH]

Molecular Oncology

Next Generation Sequencing (NGS)

Calreticulin type 1 / type 2 Mutation Analysis [M CALR]
IgVH Somatic Hypermutation [M IgVH]
JAK2 Exon 12 Mutation [M JAK2 EX12]
MPL Exon 10 Mutation [M MPL]
MYD88 p.L265P Mutation [M MYD88]
Myeloid Neoplasms Extended Mutation Panel [M MYELOID EXTENDED]
JAK2 (V617F and Exon 12), CALR (Type 1 and 2), MPL, ASXL1,
CBL, CSF3R, ETV6/TEL, EZH2, IDH1, IDH2, KIT, KRAS, NRAS,
RUNX1, SETB1, SF3B1, SRSF2, TET2, TP53

Polymerase Chain Reaction (PCR)

ABL Kinase Gene Mutation; Gleevec® Resistance [M ABL G*]
AML Mutation Analysis - FLT3, NPM1 [M AML]
B-cell Immunoglobulin Heavy Chain Gene Rearrangement
[M BCELL]
B-cell Immunoglobulin Kappa Light Chain Rearrangement
[M IGK]
BCR/ABL qRT PCR Major p210 & Minor p190 transcripts
[M BCR ABL]
CEBPA Mutation [M CEBPA*]
FLT3 Mutation [M FLT3*]
JAK2 V617F Mutation [M JAK2]
KIT Mutations in AML [M KIT AML]
KIT D816V Mutation [M KIT P*]
NPM1 Mutation [M NPM1]
PML RARA Short and Long form by qRT PCR [M PML RARA*]
T-Cell Receptor Gamma Gene Rearrangement [M TCR]



Hematology Oncology

Fluorescence in situ Hybridization (FISH)

Hematology Panels

Burkitt / "Double Hit" Large B-cell Lymphoma Panel [F BURKITT]
[C-MYC, BCL2, BCL6]

Chronic Lymphocytic Leukemia Panel [F CLL]
[MYB (6q23), ATM (11q22.3), +12, DLEU1 (13q14.3), TP53 (17p13)]

Myelodysplasia Panel [F MDS] [-5/5q-, -7/7q-, +8, 20q-]

Myeloproliferative Neoplasms Panel [F MPD]
[+8, t(9;22), 13q-, 20q-]

Plasma Cell Neoplasm Panel [F MM]
[1p-, 1q+, +5, +9, t(11;14), 13q-, +15, 17p-] reflex t(4;14) / t(14;16)

Hematology Probes

AML1(RUNX1)/ETO(RUNX1) t(8;21) [F AML ETO]

ATM/CEP11 deletion 11q22.3 [F ATM]

BCL6 3q27 rearrangement [F BCL6]

BCR/ABL1 t(9;22) [F BCR ABL]

CBFB t(16;16), inv(16) [F CBFB]

C-MYC 8q24 rearrangement [F CMYC]

Deletion 7q22 [D7S796, D7S658]/7q31.2 [D7S486] [F 7q]

Deletion 13q14.3 [F D1314]

Deletion 20q12 [F D20]

EGR1 5q deletion, monosomy 5 [F EGR1]

FIPIL1/PDGFR4 4q12 gene rearrangement [F 4q12]

IGH 14q32 rearrangement [F IGH*]

IGH/BCL1 (CCND1) t(11;14) [F BCL1]

IGH/BCL2 t(14;18) [F BCL2]

IGH/FGFR3 t(4;14) [F FGFR3]

IGH/MAF t(14;16) [F IGH MAF]

IGH/MALT1 t(14;18) [F IGH MALT]

IGH/MYC t(8;14) [F IGH MYC*]

MALT1 18q21 rearrangement [F MALT]

MLL (KMT2A) 11q23 Gene Rearrangement [F MLL]

MYB 6q deletion [F MYB]

PDGFRB Gene Rearrangement [F PDGFRB]

PML/RARA t(15,17) [F PML RARA]

TP53 17p13 deletion [F P53]

Trisomy 5, 9, 15 [F T5T9T15]

Trisomy 8 [F T8]

Women's Health

STD and Infectious Disease

Chlamydia Trachomatis, Qualitative by Aptima COMBO® 2 TMA [CT]

Human Papillomavirus Genotyping [HPV G]

Human Papillomavirus High Risk by Aptima HPV [HPV HR]

Herpes Simplex Virus Type 1 and 2 Qualitative by PCR [HSV]

Neisseria Gonorrhoeae Qualitative by Aptima COMBO® 2 TMA [NG]

Trichomonas Vaginalis by Aptima [TV]

Other

Fluorescence in situ Hybridization (FISH)

Bladder Cancer Panel [+3,+7,+17,9p21-] [F URO]

Molar Pregnancy Panel [+13,+18,+21, X, Y] [FP ANEU*]

Cytogenetics

Chromosome Analysis Peripheral Blood (Constitutional) [CYTO PB]

Chromosome Analysis Products of Conception [CYTO POC]

*Performed by affiliate laboratory

Revised 18APR2019

